Rome IV Diagnostic Criteria for Centrally Mediated Abdominal Pain Syndrome (CAPS)

Apply the Rome IV diagnostic criteria for Centrally Mediated Abdominal Pain Syndrome (CAPS). Evaluate continuous abdominal pain, relationship to physiological events, functional impairment, and exclusion of other conditions. Free online clinical calculator for educational use.

Rome IV CAPS Diagnostic Criteria

Check the criteria that apply to the patient. The Rome IV criteria for CAPS require all of the following to be present for the last 3 months, with symptom onset at least 6 months before diagnosis.

Required criteria (all must be met)

All of the following criteria must be present for a positive diagnosis.

Disclaimer: The Rome IV diagnostic criteria for CAPS are an educational clinical decision-support tool. They do not replace comprehensive clinical evaluation, appropriate diagnostic workup, or clinical judgment. CAPS is typically associated with psychiatric comorbidity, but there is no specific psychological profile that can be used for diagnosis. Always ensure that other causes of chronic abdominal pain have been appropriately excluded before applying these criteria.

Rome IV Criteria for CAPS: formula, variables, and clinical context

Overview

Centrally Mediated Abdominal Pain Syndrome (CAPS), formerly known as Functional Abdominal Pain Syndrome (FAPS), is a disorder of gut-brain interaction classified under Rome IV as D1 (Centrally Mediated Disorders of Gastrointestinal Pain). CAPS is characterized by continuous or nearly continuous abdominal pain that is often severe, only rarely related to gut function, and associated with significant loss of daily functioning. It is distinguished from other functional GI disorders by its strong central component and relative independence from motility disturbances, resulting from central sensitization with disinhibition of pain signals rather than increased peripheral afferent excitability.

Diagnostic criteria

Must include all of the following for the last 3 months, with symptom onset at least 6 months before diagnosis:

#	Criterion	Description
1	Continuous abdominal pain	Continuous or nearly continuous abdominal pain occurring on most days
2	Independence from physiological events	No or only occasional relationship of pain with physiological events (e.g., eating, defecation, or menses). Some degree of GI dysfunction may be present.
3	Functional impairment	Pain limits some aspect of daily functioning, including work, intimacy, social/leisure, family life, and caregiving for self or others
4	Pain authenticity	The pain is not feigned (factitious disorder and malingering have been excluded)
5	Exclusion of other conditions	Pain is not explained by another structural or functional gastrointestinal disorder or other medical condition

Interpretation: If all five criteria are met, the patient fulfills the Rome IV diagnostic criteria for CAPS.

Associated features (not diagnostic)

The following features are commonly observed in CAPS patients but are neither required for diagnosis nor specific to CAPS:

Feature	Description
Psychiatric comorbidity	Anxiety, depression, and somatization are common but there is no specific psychological profile diagnostic of CAPS
Extraintestinal pain	Patients frequently report other painful somatic symptoms (e.g., fibromyalgia, chronic fatigue syndrome, musculoskeletal pain)
History of aversive events	History of unresolved losses, sexual abuse, or physical abuse is common and may explain severity but is not diagnostic
Maladaptive symptom behaviors	Frequent healthcare visits, multiple surgical interventions (often for "adhesions"), and pain described in emotional terms over large anatomic areas

CAPS vs. irritable bowel syndrome (IBS)

CAPS and IBS share chronic abdominal pain but differ in key ways. CAPS may represent the far end of the IBS severity spectrum, where psychosocial factors and generalized central hypersensitivity predominate.

Feature	IBS (Rome IV)	CAPS (Rome IV)
Pain character	Recurrent, often colicky; related to defecation	Continuous or nearly continuous; widespread
Relation to bowel function	Pain associated with change in stool frequency or form	No or only occasional relationship to physiological events
Pain predominance	Pain is one of several symptoms (bloating, altered stool)	Pain is the central, predominant complaint, almost to the exclusion of other symptoms
Central component	Peripheral afferent input plays a significant role	Strong central component; pain driven by central sensitization and disinhibition
Functional impairment	Variable; can be mild to severe	Required; pain limits daily functioning across multiple domains

Pathophysiology

The biology of CAPS is similar to other chronic visceral pain disorders. Key pathophysiologic mechanisms include:

Central sensitization: Altered central sensory processing with functional and structural abnormalities in sensory (mid-cingulate, insular, somatosensory cortices, thalamus), emotional arousal (anterior cingulate cortex, amygdala), and prefrontal cortical modulatory regions.
Descending pain disinhibition: Modulation of descending pain regulatory pathways in the brainstem by cortical regions can lead to exaggerated sensitivity to both noxious and innocuous stimuli.
Altered brain structure: Decreased gray matter volume in insula, amygdala, cingulate, and brainstem regions, with early life trauma potentially contributing to these differences.
Genetic and environmental factors: Complex genetic influences (serotonin reuptake, mucosal barrier function, cytokine genes) combined with adverse early life events and psychosocial stressors determine effectiveness of endogenous pain modulation.
Psychological amplification: Depression, anxiety, pain catastrophizing, fear avoidance, and passive pain coping all amplify the experience of pain.

Management considerations

Approach	Details
Patient-physician relationship	Core of all evaluation and management; active listening, empathy, validation, realistic goal-setting, and shared decision-making
Tricyclic antidepressants (TCAs)	Most widely used pharmacologic agents for CAPS; analgesic effect is independent of antidepressant effect and often effective at low doses (e.g., amitriptyline, desipramine, nortriptyline)
SNRIs	Duloxetine, venlafaxine, and milnacipran have dual analgesic and antidepressant effects; an attractive option in patients with comorbid depression
Psychological treatment	Cognitive-behavioral therapy, psychodynamic-interpersonal therapy, mindfulness/acceptance-based therapies, and hypnotherapy; combined with pharmacotherapy, effect size can be 50% or more than either monotherapy
Opioid avoidance	Narcotic analgesics should be avoided due to risk of addiction and narcotic bowel syndrome (NBS)/opioid-induced GI hyperalgesia, which paradoxically worsens pain

Epidemiology

Prevalence ranges from 0.5% to 2.1%, making CAPS less common than IBS, FD, or functional heartburn.
CAPS is 1.5 to 2 times more common in women, with peak prevalence in the fourth decade of life (ages 35 to 44).
Approximately 80% of CAPS patients have consulted a physician, with half seeing a physician 1 to 3 times per year specifically for abdominal pain.
CAPS patients in one UK study required 5.7 consultant visits, 6.4 endoscopic or imaging investigations, and 2.7 surgical interventions over 7 years of follow-up.
In the US, CAPS patients missed a mean of 11.8 days of work in the previous year, 3 times more than subjects without abdominal symptoms.

Limitations

Diagnosis of exclusion: CAPS requires that other structural and functional GI disorders have been appropriately excluded, which may involve extensive workup before the diagnosis can be established.
Overlap with IBS: CAPS may represent the severe end of the IBS spectrum, and distinguishing between the two can be challenging in patients with some bowel-related symptoms.
Subjective criteria: Several criteria (pain not feigned, limits daily function) rely on clinical judgment rather than objective measures.
Coexisting conditions: CAPS may coexist with other structural or functional diagnoses, complicating the clinical picture and making attribution of pain challenging.
Prior surgical interventions: Many CAPS patients have undergone multiple, possibly unnecessary, surgical interventions (particularly hysterectomy and exploratory laparotomy) that may further complicate evaluation.

Key references

Keefer L, Drossman DA, Guthrie E, et al. Centrally mediated disorders of gastrointestinal pain. Gastroenterology. 2016;150(6):1408-1419.
Drossman DA. Functional abdominal pain syndrome. Clin Gastroenterol Hepatol. 2004;2(5):353-365.
Sperber AD, Drossman DA. Functional abdominal pain syndrome: constant or frequently recurring abdominal pain. Am J Gastroenterol. 2010;105(4):770-774.
Clouse RE, Mayer EA, Aziz Q, et al. Functional abdominal pain syndrome. Gastroenterology. 2006;130(5):1492-1497.
Grover M, Drossman DA. Functional abdominal pain. Curr Gastroenterol Rep. 2010;12(5):391-398.

Practice caveats

CAPS is a positive diagnosis that requires meeting all five criteria, but it is also a diagnosis of exclusion. Before applying these criteria, ensure that structural and metabolic disorders have been appropriately evaluated and excluded.
Abdominal pain from non-digestive organs (urinary, gynecologic) should be excluded before establishing a diagnosis of CAPS.
Adhesions can cause symptoms of acute or subacute obstruction (and associated pain), but there is no good evidence that adhesions themselves cause the chronic, unrelenting pain typical of CAPS.
Opioids should be avoided in CAPS management due to the risk of narcotic bowel syndrome, which paradoxically worsens abdominal pain with continued or escalating opioid use.
Patients meeting CAPS criteria with a longstanding history of pain behaviors, relevant psychosocial correlates, and no alarm features rarely have an alternative specific medical etiology discovered on further investigation.

Overview

Centrally Mediated Abdominal Pain Syndrome (CAPS), formerly known as Functional Abdominal Pain Syndrome (FAPS), is a chronic disorder of gut-brain interaction characterized by continuous or nearly continuous abdominal pain that is not adequately explained by structural or other functional gastrointestinal conditions. The Rome IV classification (2016) reclassified FAPS under the new designation CAPS to better reflect the central nervous system mechanisms believed to drive and maintain the pain experience.

CAPS belongs to the broader category of Centrally Mediated Disorders of Gastrointestinal Pain (Category A) within the Rome IV framework. It is distinguished from other functional gastrointestinal disorders (FGIDs), now termed disorders of gut-brain interaction (DGBIs), by the absence of a consistent relationship between pain and physiological events such as eating, defecation, or menstruation, and by the dominance of central sensitization and altered pain modulation rather than peripheral gastrointestinal dysfunction.

Historical Context and Evolution of the Terminology

The recognition of chronic abdominal pain without an identifiable organic cause has evolved considerably over successive Rome iterations. The Rome I criteria (1994) first acknowledged functional abdominal pain as a discrete entity. Rome II (1999) and Rome III (2006) refined the definition under the heading Functional Abdominal Pain Syndrome (FAPS), emphasizing the distinction from irritable bowel syndrome (IBS) and functional dyspepsia (FD). The key differentiator has always been the absence of a consistent relationship between the pain and bowel habits or meals.

With Rome IV (2016), the nomenclature shifted to Centrally Mediated Abdominal Pain Syndrome to underscore the pathophysiological understanding that the pain is generated or amplified by central mechanisms rather than peripheral gut dysfunction. This terminological change also serves to reduce the stigma associated with the word "functional," which patients and clinicians alike sometimes interpreted as implying the pain is imaginary or psychosomatic.

Epidemiology

CAPS is relatively uncommon compared with other DGBIs. Population-based estimates suggest a prevalence of approximately 0.5% to 2% in the general population, although precise figures are difficult to establish because many patients carry alternative diagnoses such as IBS or chronic pelvic pain. CAPS is more frequently reported in women, with a female-to-male ratio of approximately 3:2 to 2:1 across studies.

The disorder typically presents in the third to fifth decades of life. Patients with CAPS account for a disproportionate share of healthcare utilization, including emergency department visits, specialist referrals, opioid prescriptions, diagnostic procedures, and surgical interventions. The economic burden, encompassing direct medical costs and indirect costs from lost productivity, is substantial.

Pathophysiology

Central Sensitization

The cardinal pathophysiological feature of CAPS is central sensitization: an amplification of nociceptive signaling within the spinal cord and brain that occurs independently of ongoing peripheral input. In central sensitization, dorsal horn neurons exhibit heightened excitability, reduced activation thresholds, and expanded receptive fields. The result is that normally innocuous visceral stimuli are perceived as painful (visceral allodynia) and mildly painful stimuli produce exaggerated pain responses (visceral hyperalgesia).

Altered Descending Modulation

Under normal circumstances, descending inhibitory pathways originating in the brainstem (particularly the periaqueductal gray and rostral ventromedial medulla) modulate nociceptive transmission at the spinal cord level. In patients with CAPS, functional neuroimaging studies have demonstrated reduced activity in these descending inhibitory circuits and, in some cases, enhanced descending facilitation. The net effect is a failure to suppress or "gate" visceral pain signals, allowing them to reach conscious awareness with amplified intensity.

Cortical Processing Abnormalities

Functional MRI and PET studies have revealed altered activation patterns in brain regions involved in the affective and cognitive dimensions of pain in CAPS patients. Key regions implicated include the anterior cingulate cortex (ACC), prefrontal cortex (PFC), insular cortex, and somatosensory cortex. The ACC, in particular, plays a dual role in pain affect (the unpleasantness of pain) and in cognitive control. Dysfunction in ACC-PFC connectivity may contribute to catastrophizing, hypervigilance to bodily sensations, and impaired engagement of coping strategies.

Neuroplasticity and Chronification

Chronic pain states, including CAPS, are increasingly understood through the lens of maladaptive neuroplasticity. Prolonged nociceptive input (which may have originally arisen from a peripheral source such as infection, inflammation, or surgery) can induce long-term potentiation-like changes in spinal and supraspinal circuits that persist long after the initial trigger resolves. This phenomenon explains why many CAPS patients report a history of an identifiable precipitating event (e.g., abdominal surgery, infectious gastroenteritis, physical trauma) followed by pain that persists and gradually becomes decoupled from any peripheral correlate.

Psychosocial and Biopsychosocial Contributions

CAPS is strongly associated with psychiatric comorbidity. Anxiety disorders, major depressive disorder, somatization disorder, and post-traumatic stress disorder (PTSD) are overrepresented among CAPS patients. A history of adverse childhood experiences, including physical, emotional, or sexual abuse, is more prevalent in CAPS than in other DGBIs. These psychosocial factors are not merely comorbid; they actively modulate pain processing through shared neurobiological substrates (e.g., the hypothalamic-pituitary-adrenal [HPA] axis, monoaminergic neurotransmitter systems, and corticolimbic circuits).

Rome IV Diagnostic Criteria

The diagnosis of CAPS requires that all five of the following criteria are met. The criteria must be fulfilled for the last 3 months, with symptom onset at least 6 months before diagnosis.

Criterion 1: Continuous or Nearly Continuous Abdominal Pain

The patient reports abdominal pain that is present on most days and is either constant, nearly constant, or frequently recurring. The pain may fluctuate in intensity but does not remit for extended periods. Brief pain-free intervals do not exclude the diagnosis, provided that pain is the dominant experience over time. The pain is typically diffuse, poorly localized, and does not conform to a specific dermatomal distribution. It may be described as deep, dull, aching, or pressure-like, although the descriptors vary widely among patients.

Criterion 2: No or Only Occasional Relationship to Physiological Events

Unlike IBS (where pain is related to defecation) or functional dyspepsia (where pain is related to meals), the pain in CAPS does not show a consistent temporal association with eating, defecation, menstruation, or other physiological events. Patients may report occasional worsening with meals or around the time of bowel movements, but this relationship is inconstant and does not account for the pattern of pain. If a reliable and reproducible relationship with a physiological event is identified, an alternative diagnosis (e.g., IBS, functional dyspepsia) should be considered.

Criterion 3: Pain Limits Some Aspect of Daily Functioning

The pain must have a demonstrable impact on the patient's ability to carry out normal daily activities. Functional impairment can manifest in any domain: work performance, social or leisure activities, intimate relationships, family responsibilities, or self-care. This criterion underscores the severity threshold required for a CAPS diagnosis and distinguishes clinically significant chronic abdominal pain from mild or intermittent discomfort that does not interfere with function. Standardized instruments such as the Pain Disability Index (PDI) or the WHO Disability Assessment Schedule (WHODAS 2.0) may be used to quantify impairment.

Criterion 4: The Pain Is Not Feigned

Clinical assessment supports that the patient is not fabricating or deliberately exaggerating the pain. Factitious disorder (deliberate symptom production for the purpose of assuming the sick role) and malingering (intentional symptom exaggeration for external gain such as financial compensation or avoidance of responsibilities) must be excluded through clinical judgment. This criterion is assessed clinically and does not require a specific test or instrument. Behavioral inconsistencies, symptom discordance, or contextual red flags may prompt further evaluation, but it is important to avoid an adversarial stance, as the vast majority of chronic pain patients report their symptoms honestly.

Criterion 5: Pain Is Not Explained by Another Condition

Other structural or functional gastrointestinal disorders, or other medical conditions, that could account for the pain have been appropriately evaluated and excluded. This does not mandate exhaustive testing but requires a clinically reasonable workup guided by the patient's symptom profile, age, and risk factors. Conditions to consider and rule out include inflammatory bowel disease (IBD), chronic pancreatitis, endometriosis, adhesive disease, abdominal wall pain (e.g., anterior cutaneous nerve entrapment syndrome [ACNES]), chronic mesenteric ischemia, IBS with predominant pain, narcotic bowel syndrome/opioid-induced gastrointestinal hyperalgesia, and relevant extra-abdominal causes (e.g., thoracolumbar radiculopathy, porphyria, familial Mediterranean fever).

Temporal Requirement

The Rome IV criteria stipulate that symptoms must have been present for the last 3 months and that the onset of symptoms occurred at least 6 months before the time of diagnosis. This temporal filter helps to distinguish CAPS from acute or subacute pain syndromes and ensures that the chronicity inherent in the condition is captured. In clinical practice, most patients who ultimately receive a CAPS diagnosis have experienced pain for considerably longer than 6 months, often for years, before the diagnosis is formally established.

Clinical Features and Presentation

Pain Characteristics

CAPS pain is characteristically diffuse, non-localized, and described in vague terms. Patients may report that the pain is "everywhere" in the abdomen or that it shifts location over time. The quality of pain varies: it may be aching, burning, cramping, or pressure-like. The intensity is typically moderate to severe and, by definition, sufficient to interfere with daily function. Importantly, the pain tends to be constant rather than episodic, which distinguishes it from conditions like biliary colic, intermittent bowel obstruction, or cyclical vomiting syndrome.

Associated Symptoms

Patients with CAPS frequently report extraintestinal pain symptoms, including chronic headache, fibromyalgia, chronic pelvic pain, temporomandibular disorder (TMD), and non-cardiac chest pain. The co-occurrence of multiple chronic pain conditions supports the concept of a generalized central pain amplification mechanism. Autonomic symptoms (e.g., dizziness, palpitations, sweating) and fatigue are also common. GI symptoms such as bloating, nausea, and altered bowel habits may be present but do not dominate the clinical picture or exhibit the consistent relationship to pain that defines other DGBIs.

Psychological Features

A significant proportion of CAPS patients exhibit comorbid psychological conditions. Anxiety, depression, somatization, and catastrophizing are highly prevalent. Sleep disturbance and poor sleep quality are frequently reported and may both contribute to and result from the chronic pain state. Patients may exhibit illness behavior characterized by frequent healthcare seeking, resistance to psychological explanations, and insistence on additional diagnostic investigations.

Differential Diagnosis

The diagnosis of CAPS is one of exclusion within the context of a positive clinical pattern. Key conditions to differentiate include:

Irritable Bowel Syndrome (IBS): Pain is related to defecation and associated with changes in stool frequency or form. While IBS and CAPS can co-exist, the primary distinguishing feature is whether pain has a consistent relationship to bowel habits.
Functional Dyspepsia (FD): Epigastric pain or discomfort related to meals, early satiation, or postprandial fullness localizes the symptoms to the gastroduodenal region and links them to eating.
Narcotic Bowel Syndrome (NBS)/Opioid-Induced GI Hyperalgesia: Patients on chronic opioid therapy who develop paradoxical worsening of abdominal pain. The pain escalates with dose increases and improves with opioid withdrawal. This diagnosis must be actively considered in any patient with chronic abdominal pain who is taking opioids.
Chronic Abdominal Wall Pain (CAWP): Localized, reproducible tenderness on palpation that worsens with abdominal wall tensing (positive Carnett sign). Anterior cutaneous nerve entrapment syndrome (ACNES) is a specific cause.
Chronic Pancreatitis: Epigastric pain radiating to the back, often related to meals and alcohol use, with potential exocrine or endocrine insufficiency.
Inflammatory Bowel Disease (IBD): Characterized by objective markers of inflammation (elevated CRP, fecal calprotectin, endoscopic findings). Chronic abdominal pain may persist in IBD patients even during mucosal remission, potentially overlapping with CAPS.
Endometriosis: Cyclical pelvic and abdominal pain in women of reproductive age, though non-cyclical pain patterns can occur in advanced disease.
Chronic Mesenteric Ischemia: Postprandial abdominal pain ("intestinal angina") with weight loss, particularly in elderly patients with cardiovascular risk factors.

Diagnostic Approach

Clinical Assessment

Diagnosis relies primarily on a thorough clinical history and physical examination. The clinician should elicit the temporal pattern of pain (continuous vs. episodic), its relationship (or lack thereof) to physiological events, the degree of functional impairment, and any prior diagnostic evaluations. A detailed psychosocial history, including screening for depression, anxiety, history of abuse, and current stressors, is essential. The physical examination is typically unremarkable, with diffuse, non-localizable tenderness and no peritoneal signs. A positive Carnett sign should prompt evaluation for abdominal wall pathology.

Laboratory and Imaging

There is no specific biomarker or imaging finding for CAPS. The role of investigations is to exclude alternative diagnoses. A reasonable baseline workup may include complete blood count (CBC), comprehensive metabolic panel (CMP), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fecal calprotectin, celiac serologies (tissue transglutaminase IgA), and abdominal imaging (ultrasound or CT) if not previously performed. Endoscopy (upper and/or lower) may be indicated based on age, alarm features, or prior testing gaps. The extent of investigation should be proportionate to the clinical scenario, and clinicians should resist the temptation to pursue ever-more-invasive or exotic testing in the absence of specific clinical indications, as this can reinforce illness behavior and delay appropriate management.

The Importance of a Positive Diagnosis

A positive diagnostic approach, where the clinician identifies the syndrome based on its characteristic clinical features rather than solely through exclusion, is strongly recommended by the Rome Foundation. Making the diagnosis confidently and communicating it clearly to the patient is itself a therapeutic intervention. Repeated negative testing in the absence of new clinical findings should be avoided.

Management

The Therapeutic Relationship

The cornerstone of CAPS management is the establishment of an effective, empathic, and longitudinal patient-physician relationship. Patients with CAPS often feel dismissed, disbelieved, or stigmatized. A clinical approach that validates the patient's pain experience, provides a coherent explanation of the condition (using the biopsychosocial model and the concept of the gut-brain axis), sets realistic treatment expectations, and avoids confrontational language about the "reality" of the pain is essential. Continuity of care with a single coordinating clinician helps to reduce fragmented care and unnecessary investigations.

Pharmacologic Therapy

Pharmacotherapy targets the central mechanisms that drive pain amplification:

Tricyclic Antidepressants (TCAs): Low-dose TCAs (e.g., amitriptyline, nortriptyline, desipramine; starting at 10-25 mg at bedtime, titrating up to 50-150 mg as tolerated) are first-line agents. TCAs modulate norepinephrine and serotonin reuptake, enhance descending inhibitory pathways, and have independent analgesic properties. Benefits typically emerge after 4 to 6 weeks of consistent use. Side effects include sedation, dry mouth, constipation, urinary retention, and cardiac conduction effects (ECG monitoring may be warranted at higher doses).
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs): Duloxetine (60-120 mg/day) and venlafaxine (75-225 mg/day) are effective alternatives, particularly for patients who cannot tolerate TCA side effects or who have comorbid depression or generalized anxiety disorder. The dual monoaminergic mechanism parallels that of TCAs. Nausea, headache, and dizziness are common early side effects.
Augmentation Strategies: For patients with partial response to a single neuromodulator, augmentation with a second agent from a different class (e.g., adding a low-dose atypical antipsychotic such as quetiapine 25-100 mg or aripiprazole 2-5 mg to a TCA or SNRI) may be considered. Gabapentinoids (pregabalin, gabapentin) and mirtazapine are also used in select cases. Evidence for these combinations is limited and largely extrapolated from the broader chronic pain literature.
Avoidance of Opioids: Opioid analgesics are strongly contraindicated in CAPS. Opioids provide, at best, transient relief; lead to tolerance, dose escalation, and physical dependence; and can paradoxically worsen abdominal pain through narcotic bowel syndrome (opioid-induced gastrointestinal hyperalgesia). The Rome Foundation explicitly recommends against opioid use in CAPS, and opioid de-escalation should be a treatment goal for patients already on these medications.

Psychological Therapies

Psychological interventions are a critical component of multimodal CAPS management:

Cognitive Behavioral Therapy (CBT): CBT is the best-studied psychological intervention for chronic pain and targets maladaptive cognitions (catastrophizing, fear-avoidance, helplessness), dysfunctional pain behaviors (excessive rest, healthcare seeking), and coping skill deficits. CBT for chronic pain typically involves pain education, cognitive restructuring, graded activity, relaxation training, and relapse prevention.
Gut-Directed Hypnotherapy: Originally developed for IBS, gut-directed hypnotherapy has shown benefit in broader FGID populations. The technique uses hypnotic suggestion to modify visceral sensation and reduce pain-related anxiety.
Mindfulness-Based Stress Reduction (MBSR): MBSR programs teach non-judgmental awareness of bodily sensations and may reduce the affective dimension of pain (i.e., the suffering associated with pain) even when pain intensity does not change substantially.
Psychodynamic Interpersonal Therapy (PIT): PIT addresses the relational and emotional underpinnings of chronic pain and may be particularly relevant for patients with a history of trauma or interpersonal difficulties.

Multidisciplinary Pain Programs

For refractory cases, referral to a multidisciplinary pain rehabilitation program that integrates medical management, physical therapy, psychological therapy, and functional restoration is recommended. These programs emphasize self-management, reduction in pain-related disability, and return to valued activities rather than pain elimination per se.

Prognosis

CAPS is a chronic condition with a variable course. Complete resolution of pain is uncommon, but meaningful improvements in pain intensity, pain-related distress, and functional impairment are achievable with comprehensive, sustained treatment. Prognostic factors associated with better outcomes include early diagnosis and intervention, absence of opioid use, engagement with psychological therapy, strong therapeutic alliance, and the presence of active coping strategies. Poor prognostic indicators include severe psychiatric comorbidity, history of abuse, long symptom duration before diagnosis, high healthcare utilization, ongoing opioid therapy, and passive coping styles (e.g., catastrophizing, avoidance).

Special Populations

Overlap with Other Disorders of Gut-Brain Interaction

CAPS can co-exist with other DGBIs. A patient may meet Rome IV criteria for IBS or functional dyspepsia and, in addition, exhibit continuous pain that exceeds the expected pattern for those conditions. In such cases, a dual diagnosis is appropriate, and treatment should address both the peripheral and central components of the pain experience.

CAPS in the Setting of Chronic Opioid Use

Narcotic bowel syndrome (NBS) is a specific entity in which chronic opioid use leads to paradoxical worsening of abdominal pain through opioid-induced hyperalgesia. NBS and CAPS share many clinical features but are distinguished by the temporal relationship to opioid use. In patients taking chronic opioids who meet CAPS criteria, a supervised opioid taper should be attempted before the diagnosis of CAPS is confirmed, as pain may substantially improve with opioid discontinuation.

Pediatric Considerations

While CAPS as defined by Rome IV applies to adults, a related entity, Functional Abdominal Pain - Not Otherwise Specified (FAP-NOS), is recognized in the pediatric Rome IV criteria. The clinical features overlap, though the approach to diagnosis and management in children and adolescents involves additional considerations regarding developmental stage, family dynamics, and school functioning.

Key Clinical Pearls

CAPS is a diagnosis of chronic continuous abdominal pain driven by central sensitization and impaired descending pain modulation, not by peripheral GI pathology.
All five Rome IV criteria must be met, and symptoms must have been present for at least 3 months with onset at least 6 months before diagnosis.
The absence of a consistent relationship between pain and physiological events (eating, defecation, menses) is a key distinguishing feature from IBS and functional dyspepsia.
Opioid analgesics are strongly contraindicated due to the risk of narcotic bowel syndrome and lack of long-term efficacy.
First-line pharmacotherapy consists of centrally acting neuromodulators: TCAs or SNRIs.
Psychological therapies (especially CBT and gut-directed hypnotherapy) are integral components of management.
The therapeutic relationship itself is a key treatment modality: validation, education, and continuity of care are paramount.
Avoid repeated invasive testing in the absence of new clinical findings, as this reinforces illness behavior without improving outcomes.

Calculator Interpretation Guide

This calculator evaluates whether a patient meets the Rome IV diagnostic criteria for CAPS by assessing each of the five mandatory criteria. All five criteria must be endorsed for the diagnosis to be supported.

All criteria met (Positive): The patient's presentation is consistent with the Rome IV diagnosis of Centrally Mediated Abdominal Pain Syndrome, provided symptoms have been present for the required duration (3 months with onset at least 6 months prior). Clinical correlation is essential. The result does not replace clinical judgment.
One or more criteria not met (Negative): The patient does not fulfill the Rome IV criteria for CAPS. The unmet criteria should guide further diagnostic evaluation. Alternative diagnoses, including other DGBIs (IBS, functional dyspepsia), structural pathology, or extra-intestinal conditions, should be reconsidered.

This tool is intended for educational and clinical decision-support purposes only. It does not constitute medical advice and should not be used as the sole basis for clinical decisions. Always integrate the calculator result with the full clinical context, patient history, and professional judgment.